GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Cyclically Adjusted Price-to-FCF

Champions Oncology (Champions Oncology) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Champions Oncology Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Champions Oncology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Cyclically Adjusted Price-to-FCF Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Champions Oncology's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted Price-to-FCF falls into.



Champions Oncology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Champions Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Champions Oncology's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.077/130.1244*130.1244
=-0.077

Current CPI (Jan. 2024) = 130.1244.

Champions Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 0.010 100.023 0.013
201407 -0.485 100.520 -0.628
201410 -0.442 100.176 -0.574
201501 -0.426 98.604 -0.562
201504 -0.230 99.824 -0.300
201507 -0.296 100.691 -0.383
201510 -0.299 100.346 -0.388
201601 -0.099 99.957 -0.129
201604 -0.081 100.947 -0.104
201607 -0.250 101.524 -0.320
201610 -0.012 101.988 -0.015
201701 -0.076 102.456 -0.097
201704 -0.015 103.167 -0.019
201707 -0.260 103.278 -0.328
201710 0.021 104.070 0.026
201801 0.034 104.578 0.042
201804 -0.018 105.708 -0.022
201807 0.010 106.324 0.012
201810 -0.015 106.695 -0.018
201901 0.087 106.200 0.107
201904 0.008 107.818 0.010
201907 -0.088 108.250 -0.106
201910 0.045 108.577 0.054
202001 0.008 108.841 0.010
202004 0.080 108.173 0.096
202007 -0.101 109.318 -0.120
202010 0.025 109.861 0.030
202101 -0.074 110.364 -0.087
202104 -0.192 112.673 -0.222
202107 -0.052 115.183 -0.059
202110 0.046 116.696 0.051
202201 0.268 118.619 0.294
202204 0.021 121.978 0.022
202207 -0.070 125.002 -0.073
202210 0.198 125.734 0.205
202301 0.060 126.223 0.062
202304 -0.107 127.992 -0.109
202307 -0.345 128.974 -0.348
202310 0.032 129.810 0.032
202401 -0.077 130.124 -0.077

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Champions Oncology  (NAS:CSBR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Champions Oncology Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Industry
Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Champions Oncology (Champions Oncology) Headlines